- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04058756
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
March 25, 2024 updated by: Novartis Pharmaceuticals
An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments
The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
121
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: 1-888-669-6682
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
Study Locations
-
-
-
Leuven, Belgium, 3000
- Recruiting
- Novartis Investigative Site
-
Liege, Belgium, 4000
- Recruiting
- Novartis Investigative Site
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- Novartis Investigative Site
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Guangzhou, China, 510060
- Recruiting
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510515
- Completed
- Novartis Investigative Site
-
-
-
-
-
Praha 4, Czechia, 140 59
- Withdrawn
- Novartis Investigative Site
-
-
Czech Republic
-
Brno, Czech Republic, Czechia, 656 53
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Lille, France, 59037
- Completed
- Novartis Investigative Site
-
Lyon, France, 69373
- Completed
- Novartis Investigative Site
-
Marseille, France, 13273
- Completed
- Novartis Investigative Site
-
Marseille Cedex 05, France, 13885
- Active, not recruiting
- Novartis Investigative Site
-
Villejuif, France, 94800
- Active, not recruiting
- Novartis Investigative Site
-
-
-
-
-
Essen, Germany, 45147
- Recruiting
- Novartis Investigative Site
-
Heidelberg, Germany, 69120
- Recruiting
- Novartis Investigative Site
-
Jena, Germany, 07740
- Recruiting
- Novartis Investigative Site
-
Ulm, Germany, 89081
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
High West, Hong Kong
- Recruiting
- Novartis Investigative Site
-
Hong Kong, Hong Kong
- Recruiting
- Novartis Investigative Site
-
Shatin New Territories, Hong Kong
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hungary, H 1122
- Recruiting
- Novartis Investigative Site
-
Debrecen, Hungary, 4032
- Active, not recruiting
- Novartis Investigative Site
-
Debrecen, Hungary, 4032
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Napoli, Italy, 80131
- Recruiting
- Novartis Investigative Site
-
Napoli, Italy, 80131
- Completed
- Novartis Investigative Site
-
-
MI
-
Milano, MI, Italy, 20133
- Recruiting
- Novartis Investigative Site
-
Milano, MI, Italy, 20132
- Recruiting
- Novartis Investigative Site
-
Milano, MI, Italy, 20141
- Recruiting
- Novartis Investigative Site
-
Rozzano, MI, Italy, 20089
- Recruiting
- Novartis Investigative Site
-
-
MO
-
Modena, MO, Italy, 41124
- Recruiting
- Novartis Investigative Site
-
-
PN
-
Aviano, PN, Italy, 33081
- Recruiting
- Novartis Investigative Site
-
-
SI
-
Siena, SI, Italy, 53100
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Novartis Investigative Site
-
Seoul, Korea, Republic of, 05505
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Leiden, Netherlands, 2333 ZA
- Completed
- Novartis Investigative Site
-
-
-
-
-
Gdansk, Poland, 80 952
- Completed
- Novartis Investigative Site
-
Poznan, Poland, 60-693
- Active, not recruiting
- Novartis Investigative Site
-
-
-
-
-
Madrid, Spain, 28009
- Recruiting
- Novartis Investigative Site
-
Madrid, Spain, 28041
- Withdrawn
- Novartis Investigative Site
-
Madrid, Spain, 28034
- Completed
- Novartis Investigative Site
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08035
- Recruiting
- Novartis Investigative Site
-
Barcelona, Catalunya, Spain, 08036
- Recruiting
- Novartis Investigative Site
-
Hospitalet de LLobregat, Catalunya, Spain, 08907
- Recruiting
- Novartis Investigative Site
-
-
Comunidad Valenciana
-
Valencia, Comunidad Valenciana, Spain, 46010
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Zuerich, Switzerland, 8091
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Taipei, Taiwan, 10041
- Recruiting
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thailand, 10310
- Completed
- Novartis Investigative Site
-
Chiang Mai, Thailand, 50200
- Active, not recruiting
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla, Hat Yai, Thailand, 90110
- Completed
- Novartis Investigative Site
-
-
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Medical Center- New York Presbyterian
-
Principal Investigator:
- Catherine Shu
-
Contact:
- Caitlin Rogers
- Email: cr3311@cumc.columbia.edu
-
-
Oregon
-
Portland, Oregon, United States, 97123
- Recruiting
- Providence Portland Medical Center
-
Contact:
- Ashley Drokin
- Phone Number: 503-215-6805
- Email: Ashley.Drokin@providence.org
-
Principal Investigator:
- Rom Leidner
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center Uni of Te MDACC
-
Principal Investigator:
- Funda Meric-Bernstam
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject is currently enrolled in a pre-defined Novartis-sponsored study and is receiving spartalizumab as single agent or in combination with other study treatment,
- Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator.
Other protocol defined inclusion criteria may apply
Exclusion Criteria:
- Subject has been permanently discontinued from spartalizumab in the parent protocol for any reason other than enrollment in the Roll over Study
- Subject does not meet the criteria specified in the parent protocol criteria for continued study treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PDR001
All subjects in all combination will be entered in one arm
|
PDR001
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency and nature of AE and SAE by subject
Time Frame: 5 years
|
Safety data.
|
5 years
|
Number of subjects with PDR001 dose interruption and/or reduction
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects receiving PDR001
Time Frame: 5 years
|
5 years
|
Subject's exposure duration
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 31, 2019
Primary Completion (Estimated)
March 7, 2030
Study Completion (Estimated)
March 7, 2030
Study Registration Dates
First Submitted
August 13, 2019
First Submitted That Met QC Criteria
August 14, 2019
First Posted (Actual)
August 16, 2019
Study Record Updates
Last Update Posted (Actual)
March 26, 2024
Last Update Submitted That Met QC Criteria
March 25, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CPDR001X2X01B
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
Clinical Trials on PDR001
-
Palobiofarma SLNovartis; H. Lee Moffitt Cancer Center and Research InstituteCompletedNon-small Cell Lung Cancer (NSCLC)United States
-
Novartis PharmaceuticalsCompletedMetastatic Colorectal CancerSpain, Italy, Singapore, Canada, Israel, Korea, Republic of, Netherlands, Australia
-
Novartis PharmaceuticalsTerminatedCarcinoma, Non-Small-Cell LungBelgium, Germany, United States, Canada, France, Italy, Japan, Korea, Republic of, Spain
-
Yonsei UniversityWithdrawn
-
Mayo ClinicUniversity of MinnesotaNot yet recruiting
-
Novartis PharmaceuticalsTerminatedSolid Tumors and LymphomasUnited States, Australia, Netherlands, Canada, Germany, Switzerland, Japan, Spain
-
Novartis PharmaceuticalsCompletedBreast Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Renal Cancer | Hepatocellular CancerTaiwan, Germany, Italy, Austria, Switzerland, Hong Kong, Japan, Canada, United States
-
Novartis PharmaceuticalsCompletedSolid Tumors | LymphomasSpain, Canada, Singapore, Israel, Japan, United States
-
Novartis PharmaceuticalsCompletedColorectal Cancer, Triple Negative Breast Cancer, NSCLC - AdenocarcinomaUnited States, France, Taiwan, Canada, Italy, Singapore, Belgium, Spain, Israel
-
Novartis PharmaceuticalsTerminatedMelanoma | Ovarian Cancer | NSCLC | Other Solid TumorsItaly, Spain, Netherlands, France, Korea, Republic of, Switzerland, Germany, Japan, United States, Canada